J&J obtains license to GSI patents for balloon tissue dissector, avoids infringement.
This article was originally published in The Gray Sheet
GSI TO MANUFACTURE BALLOON TISSUE DISSECTION SYSTEM FOR ETHICON under a licensing and distribution deal announced July 3. The five-year agreement gives Johnson & Johnson's Ethicon Endo-Surgery a license to General Surgical Innovations' patents for tissue dissectors in the hernia repair field. As a result, Ethicon can continue to market its laparoscopic hernia repair system without infringing the GSI balloon tissue dissection system patents, GSI says. GSI hopes to begin manufacturing the dissector for Ethicon by the end of the year. Ethicon launched the device worldwide in January following 510(k) clearance in December 1995.
You may also be interested in...
Perrigo, Pfizer want the US FDA to postpone its March 1 deadline for conducting nitrosamine risk assessments. Generics exec cites“serious compliance challenges” in conducting these assessments due to difficulty in finding the right lab equipment necessary to quantify nitrosamine daily intake limits.
Deal snapshot: For $425m up front, the pharma obtains a Phase III recombination fusion protein that shows ability to improve hospitalized patients’ clinical status and reduce risk of death.
Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.